source
- Pathos does deals with AstraZeneca, China's Alphamab, seeks up to $300M Series EPathos AI is firing on all cylinders. The technology and drug development company told Endpoints News that it signed a major antibody-drug conjugate (ADC) deal with a Chinese biotech and teamed up…Endpoints · 18m ago↗ source
- FDA expands Pluvicto label, allowing most metastatic prostate cancer patients to receive the therapyThe U.S. Food and Drug Administration has approved an expanded label for Novartis’ radiopharmaceutical Pluvicto, permitting its use together with hormone therapy in metastatic prostate cancer. The…